Veracyte, INC Form 4 insider transactions

Veracyte's Chief Financial Officer, Rebecca Chambers, acquired 59,324 shares of common stock through the vesting of performance-based restricted stock units, subsequently disposing of 12,049 shares for tax obligations.

Veracyte's Chief Scientific & Medical Officer, Phillip G. Febbo, acquired 71,806 shares through PSU vesting and had 24,486 shares withheld for taxes.

Veracyte's SVP, General Counsel, Annie McGuire, acquired 50,999 shares through performance-based restricted stock unit vesting and disposed of 10,867 shares for tax withholding.

Veracyte's SVP and General Counsel, Annie McGuire, sold 10,739 shares of common stock on December 16, 2025, under a pre-arranged 10b5-1 trading plan.

Veracyte Director Karin Eastham exercised stock options and subsequently sold a portion of her common stock holdings on December 5, 2025, under a Rule 10b5-1 plan.

Veracyte's Chief Scientific & Medical Officer, Phillip G. Febbo, reported the withholding of 2,955 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Veracyte's SVP and General Counsel, Annie McGuire, reported the sale of common stock totaling 1,422 shares under a pre-arranged 10b5-1 trading plan, alongside a tax-related disposition.

Veracyte's Chief Financial Officer, Rebecca Chambers, reported the sale of 13,278 shares of common stock and tax-related withholding of 3,384 shares, all under a pre-arranged 10b5-1 plan.

Veracyte CEO Marc Stapley reported the sale of 7,668 shares and the withholding of 7,914 shares for tax obligations, all under a pre-arranged 10b5-1 plan.

Veracyte's Chief Commercial Officer, John Leite, reported the disposition of common stock shares, including tax-related withholdings and a sale under a pre-arranged 10b5-1 plan.

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, reported the withholding of 1,325 common shares for tax obligations related to restricted stock unit vesting.

Veracyte's Chief Commercial Officer, John Leite, sold 2,808 shares of common stock for $50 per share, as part of a pre-arranged 10b5-1 trading plan.

Veracyte Director Evan Jones sold 1,106 shares of common stock for approximately $50.25 per share under a pre-arranged 10b5-1 trading plan.

Veracyte Inc. Director Jens Holstein sold 10,000 shares of common stock on November 20, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, reported the sale of 10,920 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Veracyte's SVP, General Counsel, Annie McGuire, sold 6,466 shares of common stock for $40 per share as part of a pre-arranged 10b5-1 trading plan.

A director at Veracyte, Inc. executed a series of option exercises and subsequent stock sales totaling 30,000 shares acquired and 43,196 shares sold under a pre-arranged 10b5-1 plan.

Veracyte Director Karin Eastham sold 9,674 shares of common stock for a weighted average price of $40.0239 per share, executed under a pre-arranged 10b5-1 plan.

Veracyte's Chief Financial Officer, Rebecca Chambers, sold 7,000 shares of common stock for $41 per share on November 5, 2025, as part of a pre-arranged 10b5-1 plan.

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, received an award of 2,886 restricted stock units, increasing his beneficial ownership.

Phillip G. Febbo, Veracyte's Chief Scientific & Medical Officer, sold 8,349 shares of common stock for a weighted average price of $36.0174 per share under a pre-arranged Rule 10b5-1 plan.

Veracyte's Chief Commercial Officer, John Leite, sold 2,539 shares of common stock for $35 per share under a pre-arranged 10b5-1 trading plan.

Veracyte Director Robert S. Epstein exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Veracyte, Inc. SVP and General Counsel Annie McGuire reported the sale of 2,160 shares of common stock at an average price of $35.0035 per share, executed under a Rule 10b5-1 trading plan.

Veracyte's SVP, General Counsel, Annie McGuire, sold 2,283 shares of common stock for a weighted average price of $33.6923 per share pursuant to a pre-arranged 10b5-1 plan.

Veracyte CEO Marc Stapley sold 7,667 shares of common stock for approximately $30.41 per share under a pre-arranged Rule 10b5-1 trading plan.

Veracyte's Chief Financial Officer, Rebecca Chambers, reported the withholding of 5,371 common shares for tax obligations related to restricted stock unit vesting.

Veracyte's SVP, General Counsel, Annie McGuire, reported a tax-related disposition of 3,507 shares of common stock following restricted stock unit vesting.

Veracyte CEO Marc Stapley reported a disposition of 7,914 shares of common stock to cover tax obligations related to RSU vesting, not a sale.

Veracyte's Chief Scientific and Medical Officer, Phillip G. Febbo, reported a routine disposition of shares to cover tax obligations related to restricted stock unit vesting.